Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company UpdateBusiness Wire • 02/27/25
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company UpdateBusiness Wire • 01/13/25
NovoCure: PANOVA-3 Data Suggests A Potential Game-Changer For Pancreatic CancerSeeking Alpha • 12/05/24
NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study GoalsZacks Investment Research • 12/03/24
Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFieldsSeeking Alpha • 12/02/24
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer PatientsBenzinga • 12/02/24
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic CancerBusiness Wire • 12/02/24
Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic CancerBusiness Wire • 12/02/24
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in GlioblastomaBusiness Wire • 11/21/24
FDA Approves Novocure's Innovative HFE Transducer Arrays for Use With Optune Gio® for GlioblastomaBusiness Wire • 11/21/24
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer PatientsBenzinga • 10/16/24